Bone Marrow Grafts from Donors Treated with Flt3L Have More Plasmacytoid Dendritic Cells and Lead to Improved Transplant Outcomes Open Access
Ulezko Antonova, Alina (Spring 2019)
Abstract
Hematological malignancies can be cured with hematopoietic stem cell transplantation (HSCT). The source of hematopoietic stem cells (HSC) from adult donors is either bone marrow (BM) or granulocyte-colony stimulating factor mobilized peripheral blood (G-PB). A randomized, multi-center clinical trial (BMT CTN 0201) showed better overall survival (OS) and less graft-versus-host disease (GvHD) among recipients of grafts containing higher numbers of plasmacytoid dendritic cells (pDC). This was only true for recipients of BM grafts, but not recipients of G-PB grafts. Thus, BM pDC may be more effective than G-PB pDC in regulating post-transplant GvHD. Unfortunately, not all BM grafts have optimal numbers of pDC. Therefore, a method to increase pDC numbers in all BM grafts is highly significant and may offer a novel approach to prevent chronic GvHD (cGvHD). Because FMS-like receptor tyrosine kinase 3 ligand (Flt3L) up-regulates pDC proliferation and maintains pDC homeostasis, we hypothesized that Flt3L could be used as a method to increase pDC content in BM grafts. We show that s.c. administration of 300 mg/kg of Flt3L on days -4 and -1 to mice increases >3 fold the content of pDC in BM grafts without affecting the content of HSCs. Using an allogeneic transplant model (C57BL/6àB10.BR), we report that transplantation of 5 million T-cell depleted Flt3L-stimulated BM (TCD F-BM) cells plus 4 million allogeneic donor T cells resulted in improved overall survival and decreased GvHD as compared to control TCD BM plus T cells. Donor-derived T cells in recipients of F-BM were marked by decreased Th1 and Th17 polarization. Comparative analysis of mRNA from pDC sorted from human and murine donors treated with Flt3L indicated up-regulation of immunoregulatory checkpoints and adaptive immune pathways, as well as genes involved in intrathymic thymocyte selection as compared to pDC from control untreated marrow. Moreover, Flt3L-treated donors had increased intra-thymic pDC content, and allogeneic transplantation of sorted pDC from eGFP+ mice revealed increased homing of donor-derived pDC to the recipient thymus. In conclusion, we report that donor BM graft treatment with Flt3L may improve HSCT outcomes by increasing pDC content and their GvHD-regulating activity, possibly by pDC involvement in the elimination of auto-reactive T cells that would otherwise initiate GvHD.
Table of Contents
Table of Contents
I. Introduction
1. Hematopoietic Stem Cell Transplantation 1
1.1. Overview of HSCT 1
1.2. Clinical Harvesting of Cells in HSCT: BM vs G-CSF 2
1.3. Misconceptions Around the Degree of Donor Affectation Following the Two Procedures 3
1.4. Complications of HSCT 4
1.5. Survival and GvHD after Transplant 5
2. Plasmacytoid Dendritic Cells 6
2.1. Overview of pDC 6
2.2. Role of pDC in Transplant Tolerance 7
3. Pharmacological Strategies to Modify pDC Graft Content and Function 8
3.1. FMS-Like Tyrosine Kinase 3 Ligand 9
3.2. Effect of Flt3L on pDC 11
4. Potential Mechanisms for Donor pDC to Regulate Chronic GvHD 12
4.1. Possible Role of the Thymic pDC in HSCT 12
II. Hypothesis 14
III. Materials and Methods 14
1. Mice 14
2. Flt3L Treatment 15
3. T Cell Depletion and Purification 15
4. HSC and pDC Purification 15
5. pDC Characterization 16
6. Bone Marrow Transplantation 17
7. Cytospin 18
8. Tumor Cell Challenge and Bioluminescent Imaging 18
9. Gene Array Analysis 19
10. Thymic Collection and Confocal Microscopy Analysis of Recipient Thymi 21
IV. Results 21
V. Figure legends 35
VI. Figures 41
VII. Discussion and Future Directions 51
VIII. Works Cited 57
About this Honors Thesis
School | |
---|---|
Department | |
Degree | |
Submission | |
Language |
|
Research Field | |
Keyword | |
Committee Chair / Thesis Advisor |
Primary PDF
Thumbnail | Title | Date Uploaded | Actions |
---|---|---|---|
Bone Marrow Grafts from Donors Treated with Flt3L Have More Plasmacytoid Dendritic Cells and Lead to Improved Transplant Outcomes () | 2019-04-08 14:03:54 -0400 |
|
Supplemental Files
Thumbnail | Title | Date Uploaded | Actions |
---|